Abstract:Introduction: Distinguishing between inflammatory bowel disease (IBD) and functional gastrointestinal disorders is a diagnostic challenge. The need for non-invasive biomarker as a diagnostic tool in the assessment of gastrointestinal symptoms is required. The objectives of current study were to determine the spectrum of clinical features in patients tested for fecal calprotectin presenting with high levels and to compare calprotectin levels among already diagnosed patients known to have IBD as per biopsy findings and documented on patients' file with newly presenting patients who were being investigated and did not have a diagnosis. Methods: This retrospective cross-sectional study was conducted in the Department of Pathology and Laboratory Medicine and Department of Medicine, Aga Khan University, Karachi, Pakistan from January 2017 to December 2019. Subjects tested for fecal calprotectin who had elevated fecal calprotectin levels (n = 150) were included in the current study. Each patient deposited a random stool sample in an airtight container for calprotectin analysis. Biochemical analysis of calprotectin was performed by enzyme-linked immunosorbent assay using epitope calprotectin test kit (Epitope Diagnostics, Italy) on ETI-Max 3000 immunoassay analyzer (DiaSorin, Italy). A structured history form was used for data collection. Results: One hundred and fifty patients were available for inclusion in the ﬁnal analysis. Majority of the patients (n = 117, 78%) were adults (>18 years of age), and 52.7% (n = 79) were females. Median fecal calprotectin (IQR) was 317.3 μg/g (549.10 - 239.2 μg/g) in children (n = 33) and 305 μg/g (609.9 - 201.6 μg/g) in adults; the difference was statistically non-significant (p value > 0.05). On categorization according to disease, fecal calprotectin levels were significantly elevated (p value = 0.033) in IBD patients compared to normal subjects, 644 μg/g (644 - 587.8 μg/g) vs 308.5 μg/g (505.4 - 233.8 μg/g), respectively. Diarrhea (n = 13, 38.4%), abdominal cramps (n = 12, 36.4%), and weight loss (n = 11, 33.3%) were the most common complaints noted in children with high fecal calprotectin levels, whereas in adults, abdominal cramps (n = 60, 51.3%), diarrhea (n = 59, 50.4%), and weight loss (n = 46, 39.3%) were the common complaints. The median fecal calprotectin levels in children already known to have IBD (n = 3) were higher than the levels noted in children with no diagnosis (n = 30); p value > 0.05. Similarly, median fecal calprotectin levels in adults with IBD (n = 28) were higher than the levels noted in patients with no specific diagnosis (n = 91), 400.7 μg/g (656.6 - 244.3 μg/g) vs 302.7 μg/g (564.6 - 206 μg/g); p value > 0.05. Conclusion: Current study affirms that the fecal calprotectin test can be used in identifying IBD patients in all age groups.

Elevated fecal calprotectin and lactoferrin associated with small intestinal lesions in patients with Behçet disease

Upper gastrointestinal involvement of Behçet's disease in Japan: endoscopic findings and clinical features

S91 Association Between Small Bowel Lesion Activity and Fecal Calprotectin in Pediatric Crohn's Disease

Intestinal pathological changes in Behcet's disease:a clinical retrospective study

Fecal calprotectin as an inflammatory biomarker in small bowel Crohn disease

New Insight into the Features of Behçet’s Disease with Gastrointestinal Ulcer: a Cross-Sectional Observational Study

Gastrointestinal manifestations of Behçet's disease in Japan: a study of 43 patients

Endoscopic Findings of Gastrointestinal Involvement in Chinese Patients with Behcet's Disease.

Fecal calprotectin diagnostic level gradient along the small bowel in patients with Crohn's disease

Capsule Endoscopy for Behcet’s Disease-Treatment:Five Cases Reports

Ileocecal Involvement in Intestinal Behçet's Disease and Crohn's Disease: Comparison of Clinicopathological and Immunophenotypic Features.

P1230 Integrated analysis of microbiome and metabolome reveals disease-specific profiles in inflammatory bowel disease and intestinal Behcet’s disease

The Endoscopic and Clinical Characteristics of Gastrointestinal Behcet's Disease

Diagnostic Performance of a Fecal Calprotectin Assay as a Biomarker for Mayo Endoscopic Subscore in Ulcerative Colitis: Result From a Tertiary Referral Center

P259 Clinical characteristics and long-term disease course in patients with Crohn’s disease diagnosed by video capsule endoscopy; A retrospective multicentre matched case-control study

P275 Fecal calprotectin, intestinal ultrasound, and their combination for the diagnosis of Crohn’s disease

Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants

Evaluation of epicardial adipose tissue thickness and carotid intima-media thickness in children with Behçet's disease

Clinical Spectrum in a Cohort of Patients With High Fecal Calprotectin Levels

Characterization of potential salivary biomarkers in Behçet's disease

Clinical Characteristics and Risk Factors of Intestinal Involvement in Behçet’s Syndrome Patients: a Cross-Sectional Study from a Single Center